A Wow for Neoadjuvant ICI in dMMR Colon Cancer

Data from the NICHE-2 study indicate that patients with operable mismatch repair–deficient colon cancer benefit considerably from neoadjuvant immune checkpoint inhibition. A brief period of treatment with nivolumab and ipilimumab induced high pathologic response rates, did not delay surgery, and checked disease recurrence for a median of 13.1 months so far.